Red mold dioscorea: A potentially safe traditional function food for the treatment of hyperlipidemia

被引:9
作者
Chen, Chien-Li [1 ]
Pan, Tzu-Ming [1 ]
机构
[1] Natl Taiwan Univ, Coll Life Sci, Dept Biochem Sci & Technol, Taipei 10617, Taiwan
关键词
Red mold dioscorea; Monascus purpureus; Hyperlipidemia; Lovastatin; Rhabdomyolysis; COA REDUCTASE INHIBITORS; RENAL-FAILURE; MONACOLIN-K; YEAST-RICE; RHABDOMYOLYSIS; CHOLESTEROL; STATINS; LOVASTATIN; MONASCUS; HYPERCHOLESTEROLEMIA;
D O I
10.1016/j.foodchem.2012.03.019
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
A study was undertaken to evaluate whether the interaction between Monascus-fermented products and lovastatin contributes to increased risk of rhabdomyolysis. Rhabdomyolysis is a potentially dangerous side effect of statin drugs. In this study with hyperlipidemic hamsters fed lovastatin only, lovastatin with 1-fold red mold dioscorea (RMD), and lovastatin, the functional components of red mold fermented products, HMG-CoA reductase inhibitors, did not exacerbate pre-existing diseases, and actually helped in improving existing disease conditions, respectively, as compared with the control. Administration of RMD, alone or in combination with lovastatin did not cause significant rhabdomyolysis as assessed by measuring the levels of creatinine phosphokinase. Further, we did not find any study that clearly implicates the involvement of RMD, which have long been considered a food product, in liver and kidney toxicity. RMD alone or in combination with lovastatin, does not increase the risk of rhabdomyolysis, even when administered at a high dosage (including HMG-CoA reductase inhibitors >75 mg/day/adult). (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1074 / 1080
页数:7
相关论文
共 32 条
[1]  
Björnsson E, 2012, J HEPATOL, V56, P374, DOI [10.1016/j.jhep.2011.08.016, 10.1016/j.jhep.2011.07.023]
[2]  
Bonventre J, 1995, PRINCIPLES PRACTICE, P564
[3]  
Boyd E., 1935, GROWTH SURFACE AREA
[4]   Preventing renal failure in patients with rhabdomyolysis: Do bicarbonate and mannitol make a difference? [J].
Brown, CVR ;
Rhee, P ;
Chan, LK ;
Evans, K ;
Demetriades, D ;
Velmahos, GC .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2004, 56 (06) :1191-1196
[5]  
Corpier C. L., 1998, JAMA-J AM MED ASSOC, V260, P239
[6]   Beneficial cardiovascular pleiotropic effects of statins [J].
Davignon, J .
CIRCULATION, 2004, 109 (23) :39-43
[7]  
Davignon J., 1998, PLEIOTROPIC EFFECTS, P63
[8]  
Dyer Owen, 2005, BMJ, V330, P164, DOI 10.1136/bmj.330.7484.164-d
[9]   The syndrome of rhabdomyolysis: Pathophysiology and diagnosis [J].
Giannoglou, George D. ;
Chatzizisis, Yiannis S. ;
Misirli, Gesthimani .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2007, 18 (02) :90-100
[10]   Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs [J].
Graham, DJ ;
Staffa, JA ;
Shatin, D ;
Andrade, SE ;
Schech, SD ;
La Grenade, L ;
Gurwitz, JH ;
Chan, KA ;
Goodman, MJ ;
Platt, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21) :2585-2590